Real-world management of unresectable stage III non-small-cell lung cancer: Impact of durvalumab consolidation therapy in French clinical practice.

Fiche publication

Date publication

octobre 2025

Journal

Respiratory medicine and research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Chouaid C, Giraud P, Wislez M, Pichon E, Stancu A, Debieuvre D, Girard N, Pérol M, Quantin X, Ano S, Grela F, Goyard N, Fore M, Magne F, Pante V, Lemonnier-Videau L, Falchero L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41160930

Résumé

Durvalumab consolidation therapy has improved survival after chemoradiotherapy in patients with advanced non-small-cell lung cancer (NSCLC). Our three-cohort study from France described the real-world effectiveness and safety of durvalumab in unresectable stage III NSCLC.